I was in line at the UPS Store waiting to send a sample of blood to my out-of-state myeloma doctors when an impatient man behind me muttered, "C’mon, don’t you know that our days are numbered?"

A shiver went down my spine hearing him speak the odd phrase that I’d heard three other times in the previous 24 hours. In fact, "our days are numbered" was starting to echo in my brain.

Do you know what it’s like when some …

Lately I was considering just how time consuming it is for me to be a myeloma patient. Since I have been back on treatments since October of 2014, I have noticed that I now need more time to deal with myeloma.

Although I am really trying to live a normal life and not let the fact that I am taking Revlimid (lenalidomide) and dexamethasone (Decadron) get in my way, I have to admit that I am slowed …

The poten­tial new myeloma ther­apy daratumumab just got a little closer to being avail­able to U.S. multiple myeloma patients outside of clin­i­cal trials.

Johnson and Johnson (NYSE:JNJ) announced today that its Janssen sub­sid­i­ary has started the process of applying to the U.S. Food and Drug Admin­istra­tion (FDA) to have dara­tu­mu­mab approved as a new treat­ment for re­lapsed multiple myeloma.

In particular, Johnson and Johnson has started a rolling sub­mission of a biologics license appli­ca­tion to the FDA for dara­tu­mu­mab. …

There was an im­por­tant multiple myeloma-related presentation this Monday at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

The presentation summarized early results of a pilot clin­i­cal trial being conducted at the University of Pennsylvania. The trial, which is scheduled to enroll 10 re­lapsed myeloma patients, is testing a promising ap­proach to cancer treat­ment known as “chimeric an­ti­gen re­cep­tor” (CAR) T-cell ther­apy.

CAR T-cell ther­apy has generated impressive results when used to treat certain kinds of leukemia …

A poster session yesterday at the 2015 American Society of Clinical Oncology (ASCO) annual meeting was the venue for the first substantial dose of multiple myeloma-related presentations at the conference.

During the session, research results were made available for review by meeting attendees in the form of posters, each of which summarized the results of a single study. As is typically the case during such sessions, each poster was about two feet high by three or four feet in length. …

“You definitely have ONJ.”

Those were the shocking words that came out of the mouth of my oral surgeon about two months ago. The news that I had osteonecrosis of the jaw (ONJ) was totally unexpected.

Granted, I didn’t just happen to aimlessly wander into an oral surgeon’s office, open my mouth, and ask him what he saw. But I was there to have him rule out ONJ.

Instead, he ruled it in.

But his demeanor and what …

Updated results of a key Phase 1/2 trial testing the poten­tial new myeloma ther­a­py daratumumab were released this morning. The new results con­firm pre­vi­ous research indicating that single-agent dara­tu­mu­mab has notable activity as a multiple myeloma ther­apy.

Specifically, the results show that nearly one third of the trial par­tic­i­pants – who had received a median of five prior ther­a­pies – responded to single-agent dara­tumumab. The median time to disease pro­gres­sion was 3.7 months, and the esti­mated one-year over­all …